CLINICAL TRIALS PROFILE FOR CORDARONE
✉ Email this page to a colleague
All Clinical Trials for CORDARONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00300495 ↗ | Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection | Terminated | Beth Israel Deaconess Medical Center | Phase 3 | 2006-02-01 | Atrial fibrillation is a very common complication of pulmonary resection. Patients who develop atrial fibrillation require additional treatment and are more likely to stay in the hospital for longer period of time increasing the costs associated with the operation. We propose a randomized controlled trial to see if oral amiodarone given for one week before surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the incidence of atrial fibrillation in patients who received preoperative amiodarone and compare them to the incidence of atrial fibrillation in patients who did not received preoperative amiodarone. |
| NCT00420953 ↗ | Relative Bioavailability of PM101 IV and Cordarone IV | Completed | Prism Pharmaceuticals | Phase 1 | 2006-12-18 | Determine the relative bioavailability of PM101 I.V. and Cordarone I.V. |
| NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Abbott Medical Devices | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Duke Clinical Research Institute | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | St. Jude Medical | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Mayo Clinic | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CORDARONE
Condition Name
Clinical Trial Locations for CORDARONE
Trials by Country
Clinical Trial Progress for CORDARONE
Clinical Trial Phase
Clinical Trial Sponsors for CORDARONE
Sponsor Name
